Developer docs
API playgroundTry for free, no card

Search company profiles

Tiamat Sciences

Full company profile

uuid0000i9v

Namestring
Tiamat Sciences
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Tiamat Sciences is a Durham, North Carolina-based early-stage biotech founded in 2019 that produces animal-free recombinant growth factors and proteins using a plant-based expression platform. The company's core technology targets a known pain point across multiple biotechnology sectors: the high cost and environmental footprint of conventional animal-derived growth factors used in cell culture. Its product portfolio addresses three primary use cases — cellular agriculture (cultivated meat and agricultural products, which it identifies as the primary segment), regenerative medicine, and vaccine development — making its go-to-market horizontally segmented across end-markets that all require high-quality recombinant proteins.

The business model centers on the sale of recombinant protein products to researchers and developers in these target verticals, though the input does not disclose specific pricing, contract structures, or named customers. The company operates with a small team of 1-10 employees and has raised approximately $5.5 million in cumulative funding across multiple rounds since its 2019 founding, most recently a $2 million seed extension in March 2023 led by 8090 Industries with participation from a syndicate of impact- and food-tech-aligned investors including Alexandria, Cantos, Exponential Impact, Portfolia, SeedFolio, Siddhi Capital, Social Impact Capital, Sustainable Food Ventures, and True Ventures. Founder and CEO France-Emmanuelle Adil leads the company. The stated use of funds for the most recent round — accelerating product validation, expanding production, and establishing strategic partnerships — suggests the company is transitioning from pure R&D toward commercial readiness, though no commercial revenue, named customers, or production-scale milestones are evidenced in the available data.

Short descriptiontext

Tiamat Sciences is a Durham, NC-based early-stage biotech that produces animal-free recombinant growth factors and proteins using a plant-based expression platform for cellular agriculture, regenerative medicine, and vaccine development customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
recombinant proteins, growth factors, cell-culture media, cellular agriculture inputs, plant-based biotechnology
Industry2 codes
PRIMARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAKAGAI
Cultivated (Cell-Based) Protein Foods Manufacturing
Agriculture & Food Production/Food Processing & Manufacturing/Plant-Based & Alternative Protein Foods Manufacturing
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Recombinant protein products
TypeOne Time License
Description

Sale of animal-free recombinant growth factors and proteins to customers in cellular agriculture, regenerative medicine, and vaccine development sectors

finsmes.com
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tiamat Sciences produces animal-free recombinant growth factors and proteins using a proprietary plant-based expression platform. The products are sold to customers in cellular agriculture (e.g., cultivated meat producers), regenerative medicine, and vaccine development, replacing traditional animal-derived growth factors with lower-cost and lower-environmental-impact alternatives.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduced costs and environmental impact compared to traditional animal-derived growth factors
Product overview1 text field

Tiamat Sciences offers a unified product line of animal-free recombinant growth factors and proteins, produced through plant-based technology. The company's primary offering is recombinant proteins designed for cellular agriculture, regenerative medicine, and vaccine development applications. The focus is on reducing costs and environmental impact compared to traditional animal-derived growth factors.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ACROBiosystems is a major recombinant protein and reagent manufacturer with a strong focus on cell-culture and bioprocessing applications. It is a direct peer in serving cultivated-meat and cell-therapy customers with growth factors and cytokines.

TypeBroad incumbent
Description

FUJIFILM Irvine Scientific manufactures cell-culture media and reagents for cell therapy, regenerative medicine, and cell-cultured food applications. It is a broad incumbent supplying the same downstream customers Tiamat serves, including cultivated-meat producers.

TypeDirect peer
Description

Bio-Techne (R&D Systems brand) is a leading manufacturer of recombinant proteins and growth factors for research, diagnostics, and cellular agriculture. It is the most direct incumbent competitor to Tiamat in selling recombinant growth factors to the cultivated-meat and cell-therapy markets.

TypeDirect peer
Description

Sino Biological is a large recombinant protein manufacturer serving research, diagnostic, and therapeutic development markets globally. It is a direct peer in the recombinant growth factor and protein production business Tiamat operates in.

TypeBroad incumbent
Description

Cytiva provides cell-culture media, process solutions, and bioprocessing equipment to the broader biotech and cell-therapy industries. It is a broad incumbent whose cell-culture media and process-development services overlap with Tiamat's cellular-agriculture and regenerative-medicine customers.

TypeBroad incumbent
Description

Through its Gibco brand and recent acquisition of PeproTech, Thermo Fisher is the dominant supplier of cell-culture media, sera, and recombinant growth factors. Tiamat's plant-based, animal-free growth factors compete directly with Gibco's portfolio in cellular agriculture and regenerative medicine.

TypeDirect peer
Description

Miltenyi Biotec manufactures recombinant proteins, cytokines, and growth factors for cell and gene therapy and cell-culture applications. It is a direct peer in selling high-purity recombinant proteins to the regenerative-medicine and cellular-agriculture markets Tiamat targets.

TypeDirect peer
Description

Stemcell Technologies supplies cell-culture media, growth factors, and reagents for stem-cell research and regenerative medicine. Its catalog overlaps directly with Tiamat's regenerative-medicine and cellular-agriculture use cases.

TypeEmerging player
Description

Qkine specializes in animal-free, recombinant growth factors and cytokines for stem-cell research and regenerative medicine. It is an emerging peer with a very similar animal-free positioning to Tiamat, focused on the same research and cell-therapy customer base.

TypeEmerging player
Description

Future Fields develops animal-free, recombinant growth factors specifically for the cultivated-meat industry using a fruit-fly-based expression platform. It is the most direct emerging peer to Tiamat, targeting the same primary customer segment with a similar animal-free value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tiamat Sciences

Tiamat Sciences is a Durham, NC-based early-stage biotech that produces animal-free recombinant growth factors and proteins using a plant-based expression platform for cellular agriculture, regenerative medicine, and vaccine development customers.

What Tiamat Sciences does

Tiamat Sciences is a Durham, North Carolina-based early-stage biotech founded in 2019 that produces animal-free recombinant growth factors and proteins using a plant-based expression platform. The company's core technology targets a known pain point across multiple biotechnology sectors: the high cost and environmental footprint of conventional animal-derived growth factors used in cell culture. Its product portfolio addresses three primary use cases — cellular agriculture (cultivated meat and agricultural products, which it identifies as the primary segment), regenerative medicine, and vaccine development — making its go-to-market horizontally segmented across end-markets that all require high-quality recombinant proteins.

The business model centers on the sale of recombinant protein products to researchers and developers in these target verticals, though the input does not disclose specific pricing, contract structures, or named customers. The company operates with a small team of 1-10 employees and has raised approximately $5.5 million in cumulative funding across multiple rounds since its 2019 founding, most recently a $2 million seed extension in March 2023 led by 8090 Industries with participation from a syndicate of impact- and food-tech-aligned investors including Alexandria, Cantos, Exponential Impact, Portfolia, SeedFolio, Siddhi Capital, Social Impact Capital, Sustainable Food Ventures, and True Ventures. Founder and CEO France-Emmanuelle Adil leads the company. The stated use of funds for the most recent round — accelerating product validation, expanding production, and establishing strategic partnerships — suggests the company is transitioning from pure R&D toward commercial readiness, though no commercial revenue, named customers, or production-scale milestones are evidenced in the available data.

Tiamat Sciences firmographics

Firmographics
Name
Tiamat Sciences
Website
https://tiamat-sciences.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Tiamat Sciences is a Durham, NC-based early-stage biotech that produces animal-free recombinant growth factors and proteins using a plant-based expression platform for cellular agriculture, regenerative medicine, and vaccine development customers.
Ownership category
akta.pro rank

Tiamat Sciences industry classification

Industry
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYAFAJAHAL
Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins)
Agriculture & Food Production/Food Ingredients & Additives/Proteins & Protein Ingredients (Plant/Animal Proteins, Protein Isolates/Concentrates)
SECONDARYAFAKAGAI
Cultivated (Cell-Based) Protein Foods Manufacturing
Agriculture & Food Production/Food Processing & Manufacturing/Plant-Based & Alternative Protein Foods Manufacturing

Keywords

  • Recombinant proteins
  • Growth factors
  • Cell-culture media
  • Cellular agriculture inputs
  • Plant-based biotechnology

Where Tiamat Sciences is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Tiamat Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

  1. Recombinant protein products: Sale of animal-free recombinant growth factors and proteins to customers in cellular agriculture, regenerative medicine, and vaccine development sectors

Go-to-market motion1 record

Tiamat Sciences product offering

Product offering

Core offering

Tiamat Sciences produces animal-free recombinant growth factors and proteins using a proprietary plant-based expression platform. The products are sold to customers in cellular agriculture (e.g., cultivated meat producers), regenerative medicine, and vaccine development, replacing traditional animal-derived growth factors with lower-cost and lower-environmental-impact alternatives.

Product overview

Tiamat Sciences offers a unified product line of animal-free recombinant growth factors and proteins, produced through plant-based technology. The company's primary offering is recombinant proteins designed for cellular agriculture, regenerative medicine, and vaccine development applications. The focus is on reducing costs and environmental impact compared to traditional animal-derived growth factors.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Reduced costs and environmental impact compared to traditional animal-derived growth factors

Companies that use Tiamat Sciences

Customer profile

Segments3 records

Ideal customer profiles1 record

Tiamat Sciences technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Tiamat Sciences partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Tiamat Sciences competitors and assessment

Company assessment

Direct peers

  • ACROBiosystems: ACROBiosystems is a major recombinant protein and reagent manufacturer with a strong focus on cell-culture and bioprocessing applications. It is a direct peer in serving cultivated-meat and cell-therapy customers with growth factors and cytokines.
  • Bio-Techne: Bio-Techne (R&D Systems brand) is a leading manufacturer of recombinant proteins and growth factors for research, diagnostics, and cellular agriculture. It is the most direct incumbent competitor to Tiamat in selling recombinant growth factors to the cultivated-meat and cell-therapy markets.
  • Sino Biological: Sino Biological is a large recombinant protein manufacturer serving research, diagnostic, and therapeutic development markets globally. It is a direct peer in the recombinant growth factor and protein production business Tiamat operates in.
  • Miltenyi Biotec: Miltenyi Biotec manufactures recombinant proteins, cytokines, and growth factors for cell and gene therapy and cell-culture applications. It is a direct peer in selling high-purity recombinant proteins to the regenerative-medicine and cellular-agriculture markets Tiamat targets.
  • Stemcell Technologies: Stemcell Technologies supplies cell-culture media, growth factors, and reagents for stem-cell research and regenerative medicine. Its catalog overlaps directly with Tiamat's regenerative-medicine and cellular-agriculture use cases.

Broad incumbents

  • FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific manufactures cell-culture media and reagents for cell therapy, regenerative medicine, and cell-cultured food applications. It is a broad incumbent supplying the same downstream customers Tiamat serves, including cultivated-meat producers.
  • Cytiva (Danaher): Cytiva provides cell-culture media, process solutions, and bioprocessing equipment to the broader biotech and cell-therapy industries. It is a broad incumbent whose cell-culture media and process-development services overlap with Tiamat's cellular-agriculture and regenerative-medicine customers.
  • Thermo Fisher Scientific (Life Sciences / Gibco): Through its Gibco brand and recent acquisition of PeproTech, Thermo Fisher is the dominant supplier of cell-culture media, sera, and recombinant growth factors. Tiamat's plant-based, animal-free growth factors compete directly with Gibco's portfolio in cellular agriculture and regenerative medicine.

Emerging players

  • Qkine: Qkine specializes in animal-free, recombinant growth factors and cytokines for stem-cell research and regenerative medicine. It is an emerging peer with a very similar animal-free positioning to Tiamat, focused on the same research and cell-therapy customer base.
  • Future Fields: Future Fields develops animal-free, recombinant growth factors specifically for the cultivated-meat industry using a fruit-fly-based expression platform. It is the most direct emerging peer to Tiamat, targeting the same primary customer segment with a similar animal-free value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Tiamat Sciences social profiles

Digital presence

Tiamat Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tiamat Sciences leadership team

Management profile

Number of profiles

Tiamat Sciences funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tiamat Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tiamat Sciences

What does Tiamat Sciences do?

Tiamat Sciences produces animal-free recombinant growth factors and proteins using a proprietary plant-based expression platform. The products are sold to customers in cellular agriculture (e.g., cultivated meat producers), regenerative medicine, and vaccine development, replacing traditional animal-derived growth factors with lower-cost and lower-environmental-impact alternatives.

Is Tiamat Sciences a public or private company?

Tiamat Sciences is a private company. It is currently operating.

When was Tiamat Sciences founded?

Tiamat Sciences was founded in 2019. It employs 1 to 10 people.

Where is Tiamat Sciences based?

Tiamat Sciences is headquartered in Durham, United States, in the North America region.

How does Tiamat Sciences make money?

One revenue line is on record: recombinant protein products.

Who are Tiamat Sciences's main competitors?

Direct peers on record are ACROBiosystems, Bio-Techne, Sino Biological, Miltenyi Biotec and Stemcell Technologies. Broad incumbents are FUJIFILM Irvine Scientific, Cytiva (Danaher) and Thermo Fisher Scientific (Life Sciences / Gibco). Emerging players are Qkine and Future Fields.

Does Tiamat Sciences have an API?

No public API is recorded for Tiamat Sciences.

What industry is Tiamat Sciences in?

Its primary akta.pro industry code is AFAJAHAL, Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins), with a secondary code of AFAKAGAI, Cultivated (Cell-Based) Protein Foods Manufacturing. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWomen-owned Startups Collaborate Toward a Scalable and Cost-Effective Future for Sustainable BiotechnologyTiamat Sciences and BIOMILQ have collaborated to demonstrate that Tiamat's plant-based recombinant Human Prolactin is as effective as commercial alternatives while being ten times more affordable. This partnership aims to reduce production costs for cell-based food and life sciences industries by providing scalable, animal-free protein inputs.FinSMEsTiamat Sciences Raises $2M Seed ExtensionTiamat Sciences, a Durham-based biotech startup, raised a $2 million seed extension, bringing its total funding to $5.4 million. The round was led by 8090 Industries with participation from investors including True Ventures and Exponential Impact. The company plans to use the funds for product validation in cellular agriculture and regenerative medicine while preparing for production in March 2023.PR NewswireFemale-owned biotech startup, Tiamat Sciences raise an extension of $2M to accelerate product validation and strategic partnershipsTiamat Sciences announced a $2 million seed-extension financing round led by 8090 Industries to accelerate product validation and establish strategic partnerships in cellular agriculture and regenerative medicine. The funding brings the company's total raised capital to $5.4 million as it prepares for commercial production in March 2023 and plans for site expansions in North Carolina and Belgium. This investment supports Tiamat's proprietary animal-free recombinant protein technology, which aims to significantly reduce costs compared to market alternatives.FinSMEsTiamat Sciences Raises $3M in Seed FundingTiamat Sciences, a Durham, NC-based biotech startup, raised $3M in seed funding led by True Ventures with participation from Social Impact Capital and Cantos. The company manufactures animal-free proteins using a plant molecular farming platform and is preparing to expand production facilities.TechCrunchTiamat Sciences cooking up plant-based proteins for cheaper production of cellular meatTiamat Sciences raised $3 million in seed financing led by True Ventures to develop plant-based growth factors for cellular meat. The company estimates current growth factor costs $2 million per gram, aiming to reduce that 1,000 times by 2025. It plans a pilot production facility in Durham, North Carolina, and expects its first product by end of 2022.PR NewswireFemale-Owned Biotech Startup Tiamat Sciences Raises $3 Million to Manufacture Plant-Based BiomoleculesTiamat Sciences secured a $3 million seed funding round led by True Ventures to expand its plant-based manufacturing of animal-free biomolecules. The company utilizes a proprietary platform to produce key reagents for cellular agriculture and regenerative medicine at significantly lower costs than traditional fermentation methods. Tiamat plans to build a pilot facility in Durham, North Carolina, aiming to achieve a 1,000-fold cost reduction by 2025.Protein ReportTiamat Sciences: Using plants in place of bioreactors to meet the future needs of cellular agricultureTiamat Sciences is developing a plant-based molecular farming technology to produce culture media and growth factors for cell-based meats. The company claims its production system costs up to 60 times less than competitors, addressing the fact that culture media accounts for up to 80% of cell-based meat production costs.